Four Bills Would Enable Taxpayer Contributions to Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

WASHINGTON-House members have introduced four bills that would enable taxpayers to support cancer research: One bill would allow a check-off box on income tax forms to provide contributions to a new Breast and Prostate Cancer Research Fund. Two bills would permit taxpayers to designate part or all of their income tax refund to research, either through the National Institutes of Health or the Department of Veterans’ Affairs. The last bill would authorize a matching grants program to encourage states to sell special license plates to provide funds for breast cancer research.

WASHINGTON—House members have introduced four bills that would enable taxpayers to support cancer research: One bill would allow a check-off box on income tax forms to provide contributions to a new Breast and Prostate Cancer Research Fund. Two bills would permit taxpayers to designate part or all of their income tax refund to research, either through the National Institutes of Health or the Department of Veterans’ Affairs. The last bill would authorize a matching grants program to encourage states to sell special license plates to provide funds for breast cancer research.

Articles in this issue
NCI to Expand Its Support for Trials of STI-571
Patients and Physicians Differ on Chemotherapy Expectations
Neoadjuvant Weekly Paclitaxel Ups Breast Cancer Pathologic Complete Response Rates
Concurrent Chemoradiotherapy Helps Preserve Larynx
Once-Daily, Rapid-Onset Morphine Offers Alternative for Those in Severe Pain
FDA Issues New Safeguards for Children in Clinical Trials
Decision Board Helps Breast Cancer Patients Assess Chemotherapy Options, Increases Satisfaction
Over 20% of Breast Cancer Patients Risk Recurrence by Not Taking Their Tamoxifen
Selective Serotonin Reuptake Inhibitors Can Successfully Treat Depression But Not Fatigue in Cancer Patients
Leukemia Society Offers Patient Information on Use of STI-571
Hiking Cigarette Prices Discourages Teens From Taking Up the Habit
Consensus Growing for SV40 Role in Some Mesotheliomas
NCI Launches Randomized Trial of Shark Cartilage in NSCLC
Chemotherapy Common at End of Life
Can Cognitive Dysfunction in Breast Cancer Patients Be Prevented?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Related Content
FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

Tim Cortese
August 5th 2025
Article

Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 5th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission

Russ Conroy
August 5th 2025
Article

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 5th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 5th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.

FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma

Tim Cortese
August 5th 2025
Article

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.